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Summary  
 
Pre-emptive kidney transplantation is the type of transplantation that is performed before starting 
dialysis. It allows a better quality of life to the patient and significant reduction of costs in comparison with 
dialysis, and also is connected with higher survival rate of graft and patient. We present a 26-year-old patient 
diagnosed with chronic kidney disease (CKD) due to IgA nephropathy. His kidney function, despite of 
immunosuppressive therapy, gradually  decreased in time but an onset of acute enterocolitis has lead to 
significant and permanent deterioration of kidney function with the forthcoming need for renal replacement 
therapy. His mother was accepted as a living kidney donor. The left kidney of the mother was transplanted 
to the right iliac fossa of the patient. The operation went without any complications. The postoperative 
course was uneventful with induction therapy with monoclonal antibody against interleukin 2 receptor and 
standard triple immunosuppressive therapy consisting of corticosteroid, mycophenolat mofetil and 
tacrolimus. One year after the transplantation, the patient has a good functioning kidney transplant without 
any surgical or immunological complications. Conclusively, pre-emptive kidney transplantation is an 
effective treatment for patients with end-stage renal disease and it should be recommended to all patients 
where this type of treatment is possible. 
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Sažetak 
 
Preemptivna transplantacija bubrega je vrsta transplantacije koja se radi prije početka dijalitičkog 
liječenja. Ona omogućuje bolju kvalitetu života i značajno smanjenje troškova liječenja u odnosu na dijalizu, 
a također je uz nju vezano bolje preživljenje, kako presatka, tako  i bolesnika. Prikazali smo 26-godišnjeg 
bolesnika koji ima kroničnu bubrežnu bolest (KBB) uzrokovanu IgA nefropatijom. Bubrežna funkcija 
bolesnika je unatoč primijenjenoj imunosupresivnoj terapiji postupno slabila tijekom vremena, ali je jedan 
napadaj akutnog enterokolitisa doveo do značajnog i trajnog slabljenja bubrežne funkcije. Kod bolesnika se 
tada počelo razmišljati o nadomještanju bubrežne funkcije. Bolesnikova majka je prihvaćena kao živi 
darivatelj. Lijevi bubreg majke je transplantiran u desnu ilijačnu jamu. Operacija i rani postoperacijski tijek 
prošli su bez komplikacija. Postoperacijski, a kao indukcijska terapija, koristila su se monoklonska 
protutijela protiv interleukina 2 sa standardnom trojnom imunosupresivnom terapijom koja se sastojala od 
kortikosteroida, mikofenolat-mofetila i takrolimusa. Godinu dana nakon transplantacije bolesnik ima dobro 
funkcionirajući presadak bez ikakvih kirurških ili imunoloških komplikacija. Zaključno može se reći da je 
preemptivna transplantacija bubrega efikasna metoda liječenja pacijenta s kroničnim bubrežnim zatajenjem i 
treba biti preporučena u svih bolesnika u kojih se može učiniti transplantacija. 
Ključne riječi: preemptivna transplatacija, živi darivatelj, kronična bubrežna bolest, IgA nefropatija. 
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Introduction 
 
End-stage renal disease (ESRD) is a significant 
health problem worldwide with high mortality and 
morbidity rate. Nowadays, patients with ESRD have 
three types of treatments available: haemodialysis, 
peritoneal dialysis and kidney transplantation. 
According to many studies, transplantation is the best 
option for long term survival. New and more effective 
immunosuppressive drugs, growing experience              
in transplantation surgery have made kidney trans-
plantation the best treatment option.
1
 Every patient 
with ESRD is also a candidate for pre-emptive 
transplantation. Pre-emptive kidney transplantation 
(PKT) is done before the beginning of dialytic 
treatment. Current opinions support chronic kidney 
disease (CKD) patients to receive PKT when their 
glomerular filtration rate (GFR) is 15 ml per minute 
or less and preparation for transplantation should be 
started at the time of diagnosing chronic kidney 
disease. Recent studies show that PKT has better 
outcomes than nonpreemptive kidney transplantation 
(NPKT).
2,3
 The long-term patient and graft survival 
are two major motivators for choosing PKT.
1
 The 
following could be a benefit in avoiding the 
cardiovascular side effects of long-term dialysis 
treatment and lower costs in the long term.  Lower 
incidence of hypertension and infection and less acute 
rejection episode rates in PKT patients are probably 
the main reasons for these results.
1
 PKT also allows 
the prevention of complications associated with 
haemodialysis, higher haemoglobin levels before 
transplantation, less cardiovascular disease and 
coronary artery calcification rates, better compliance 
to immunosuppressive therapy and better quality of 
life. We will present a patient from our centre in 
which PKT was performed.  
 
Case report 
 
Our patient was a 26-year-old male diagnosed 
with CKD due to IgA nephropathy. The disease was 
diagnosed in 2009 when the first kidney biopsy was 
done due to subnephrotic range proteinuria with 
preserved kidney function. Therapy with angiotensin 
converting enzyme inhibitor was started  after which 
he was lost to follow up until three years later when 
he had kidney function deterioration. We performed a 
second biopsy that confirmed IgA nephropathy with 
mesangioproliferative glomerulonephritis, according 
to the Oxford classification of IgA nephropathy 
(2009) M1, E1, S1, T1.
4
 We started treatment with 
pulsative corticosteroid therapy and had to stop after 
the first dose due to acute phychosis which the patient 
developed. He was then put on prednisolone in 
standard doses with mycophenolate-mofetil. He was 
discharged with proteinuria of 0.98 g/L and serum 
creatinine of 216 μmol/L. In spite of the therapy, 
proteinuria was progressing with slow deterioration of 
kidney function. An onset of acute enterocolitis lead 
to significant and permanent loss of kidney function. 
We started preparations for PKT from a living donor 
(mother) who was accepted as donor after standard 
protocol investigations were performed. Both kidneys 
were similar in morphology and the left kidney was 
chosen (Picture 1 and 2).  
 
 
 
Picture 1 Computerized tomography reconstruction 
of renal vasculature of donor kidneys 
Slika 1. Rekonstrukcija krvnih žila bubrega donorskih 
bubrega, uz pomoć kompjuterizirane tomografije 
 
In March 2014, after standard preparation 
including induction therapy with monoclonal 
antibody against interleukin 2 receptor, the left kidney 
of the mother was transplanted into the right iliac 
fossa of the patient. Warm ischemia lasted 30 
minutes, without cold ischemia, and the whole 
operation lasted for 140 minutes. The operation went 
through without any complications. Five days after 
the operation, the drain was removed, and seven days 
later the urinary catheter was removed. The 
postoperative course was uneventful with standard 
triple immunosuppressive therapy consisting of 
corticosteroid, mycophenolat mofetil and tacrolimus. 
One year after the transplantation, the patient has 
good functioning kidney transplant with normal 
creatinine level and without any surgical or immu-
nological complications. 
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Picture 2 Computerized tomography of renal 
vasculature of donor kidneys with contrast 
Slika 2. Kompjuterizirana tomografija prikazuje 
vaskularne strukture donorskog bubrega 
 
Discussion 
 
Renal transplantation is the best type of treatment 
for the end stage chronic kidney disease in all patients 
where this type of treatment of possible. The survival 
rate of the patient and graft are better compared to 
dialytic treatment. Choosing PKT as treatment may 
reduce morbidity and mortality of patients with 
chronic kidney failure. Studies have shown that 
prolonged haemodialysis duration may be a cause of 
cardiovascular morbidities even if the transplantation 
was successful.
5
 Mange and Weir showed a 52% 
decrease of graft loss for PKT recipients after the first 
year of transplantation comparing with the NPKT 
recipients in 8481 patients.
6
 In a retrospective study 
by Kasike et al. similar results in favour of PKT were 
reported.
7
 Recent studies show evidence that PKT  
has advantages for patient and transplant survival.
8
 
Avoidance of dialysis-associated comorbidities, 
diminished immune response and cardiovascular 
complications are the main benefits of PKT.
9
 
IgA nephropathy was first described by Berger 
and Hinglais in 1968.
10
 IgA nephropathy is the most 
common primary glomerulonephritis with variable 
frequency in different parts of the world. Primary IgA 
nephropathy is an immune-complex–mediated glome-
rulonephritis defined immunohistologically by the 
presence of glomerular IgA deposits accompanied by 
a variety of histopathologic lesions. Although primary 
IgA nephropathy receives the most attention, many 
other diseases are also associated with glomerular IgA 
deposits. The most common of these is Schönlein–
Henoch purpura. This condition may indeed be 
indistinguishable from primary IgA nephropathy and 
may represent a systemic form of the disease process. 
Although primary IgA nephropathy was 
considered a benign condition for many years, it is 
now clear that a large number of cases eventually 
progress to renal failure. Indeed, IgA nephropathy is 
the main cause of end-stage renal disease in patients 
with primary glomerular disease who require renal-
replacement therapy.
10
 
Clinical presentation ranges from asymptomatic 
hematuria to rapidly progressive glomerulonephritis. 
Most commonly, patients present with macroscopic 
hematuria or microscopic hematuria and/or mild 
proteinuria. Nephrotic-range proteinuria is uncommon 
and can be seen at different stages of the disease. 
About 30% of patients with IgA nephropathy are at 
risk to reach end stage renal disease (ESRD) after 10 
years of progression of the disease. In patients with 
active and progressive IgA nephropathy (hematuria, 
proteinuria >1 g/day, increasing serum creatinine), the 
use of corticosteroids is usually associated with a 
decrease of urinary protein excretion and lower risk 
of progression to ESRD.
11
 
One of the problems of patients suffering with  
IgA nephopathy is recurrence of disease after 
transplantation. The rate of return is, according to some 
studies, relatively high with the incidence between 12 
and 53%.
12,13
 Possible risk factors for recurrence 
include the following: living-related-donor kidney, 
specific human leukocyte antigen (HLA) alleles in 
recipient including HLA-B35, HLA-DR4, HLA-B8, 
HLA-DR3, good HLA match between donor and 
recipient and high IgA concentration. The risk of 
recurrence may be higher among recipients of living-
related-donor kidneys, compared with deceased-donor 
kidneys. The causes of return of IgA nephropathy have 
still not been investigated enough and there is need for 
additional studies, basic science and clinical science to 
differentiate risks for it, so it might be predicted in the 
future. Our patient is very young and needs good 
follow up so the renal failure caused by recurrence of 
the disease could be avoided or postponed. 
Conclusively, we can say that PKT is an effective 
method in treating patients with ESRD and it should 
be considered as an option in all patients. The 
possibility of return of the primary kidney disease 
must be discussed before transplantation, especially 
with those having IgA nephropathy due to its large 
proportion of return in graft.   
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